Pembrolizumab plus lenvatinib (P+L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA).

Details

Language :

English

ISSN :

0732183X

Volume :

42

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

175074079

Full Text :

https://doi.org/10.1200/JCO.2024.42.4_suppl.422